Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immunological biologics and vaccines, announced today that an abstract has been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2019, which will be held from March 29 through April 3, 2019Read More

Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immune modulator biotherapeutics and vaccines, today announced that the China Food and Drug Administration (CFDA) has provided clearance to proceed with a clinical trial of its PIKA® rabies vaccine. The PIKA rabies vaccine has the potential to become aRead More

Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immunological biologics and vaccines, today announced the grand opening of Anderson Biotech Company Limited and Royal OncoCare Hospitality as two wholly owned subsidiaries of Yisheng Biopharma in Cambodia. The two divisions represent the first expansion of Yisheng Biopharma businessRead More

Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immunological biologics and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for its lead immuno-oncology candidate, YS-ON-001, for the treatment of pancreatic cancer. To date the US FDARead More

Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immuno-oncology products and vaccines, today announced that its first-in-class immuno-oncology product candidate, YS-ON-001, demonstrated strong anti-tumor efficacy as a standalone therapy and synergistic effect when combined with antibody blocking programmed death receptor-1 (PD-1) in multiple animal modelsRead More

Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immuno-oncology products and vaccines, today announced that the first patient with advanced stage cancer was enrolled in a Phase I immuno-oncology trial of YS-ON-001, a lead product candidate for the treatment of advanced solid tumors. YS-ON-001 isRead More

Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immuno-therapeutic products and vaccines, today announced that the company will present at annual BioPharma Asia Convention 2017 at Suntec Convention Center, Singapore. The presentation is scheduled for 12:40 PM local time on March 22, 2017. The managementRead More

Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immuno-therapeutic products and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for its lead vaccine candidate, PIKA rabies vaccine, which is an innovative rabies vaccine independently developed by YishengRead More

Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immunological therapeutics, today announced the completion of Phase I clinical trial of PIKA Hepatitis B vaccine, an investigational vaccine designed to provide both prophylactic and therapeutic benefits against hepatitis B virus infection. This vaccine candidate is a proprietary productRead More

Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immuno-therapeutic products and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for its lead product candidate, YS-ON-001, for the treatment of hepatocellular carcinoma. YS-ON-001 is a promising biological product withRead More